Applied Genetic Technologies

AGTC files IND for X-linked retinitis pigmentosa treatment

Thursday, August 10, 2017

Applied Genetic Technologies, a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, has filed an Investigational New Drug application (IND) with the FDA to conduct a phase I/II clinical trial of the company’s gene therapy product candidate for the treatment of X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene.

[Read More]